Seres Therapeutics, Inc. 8-K

What Happened

• Seres Therapeutics, Inc. (NASDAQ: MCRB) filed an 8-K (Item 5.02) reporting leadership changes effective March 2, 2026. The Board appointed director Richard N. Kender as Executive Chair and Interim Chief Executive Officer. Thomas J. DesRosier and Marella Thorell ceased serving as Co‑Presidents and Co‑CEOs but will remain Executive Vice President, Chief Legal Officer and Executive Vice President, Chief Financial Officer, respectively. Matthew Henn, Ph.D. (current Chief Scientific Officer) was named President in addition to his CSO role, and Kelly M. Brady was promoted to Executive Vice President, Chief Operating Officer.

Key Details

• Effective date: March 2, 2026; appointment disclosed in an 8‑K filed March 2, 2026.
• Richard Kender compensation: $520,000 annual base salary; target discretionary bonus = 55% of base; $250,000 one‑time signing bonus (repayable if terminated for cause or resigns without good reason before Dec 31, 2026); option grant for 200,000 shares vesting monthly over 36 months (25% of grant contingent on shareholder approval of a Plan amendment).
• Matthew Henn compensation update: base salary increased to $505,000; target bonus = 45% of base; one‑time retention bonus $230,000 (repayable if terminated for cause or resigns without good reason before Dec 31, 2026); option grant for 100,000 shares (25% subject to shareholder approval) with time‑based vesting and potential accelerated vesting around a change in control.
• Kelly Brady compensation update: base salary increased to $475,000; target bonus = 45% of base; one‑time retention bonus $230,000 (same repayment terms); increased severance and 12 months subsidized COBRA in qualifying terminations; option grant for 75,000 shares (25% subject to shareholder approval) with time‑based vesting and similar change‑in‑control protections.
• No family relationships or related‑party transactions requiring disclosure were reported for these appointees.

Why It Matters

• Leadership and compensation changes are material corporate governance events that can affect strategy execution and investor expectations. The appointment of an Executive Chair who is also Interim CEO signals a management transition at the top while retaining the CFO and Chief Legal Officer in senior roles. The equity grants and higher salaries/bonuses align incentives for the new and promoted executives but will dilute equity if the shareholder vote to increase the Plan share reserve is approved. Investors should note the effective dates, repayment conditions on sign‑on/retention bonuses, and the contingency that 25% of each option grant requires stockholder approval.